Seed · Biotech · Uppsala, Sweden · Founded 2014 · 10–15 employees
PeptiSystems develops revolutionary flow-through instruments for peptide and oligonucleotide therapeutics synthesis, addressing critical bottlenecks in pharmaceutical manufacturing. Their proprietary technology reduces production times by up to 90% and cuts raw material usage by 70%, enabling scalable and sustainable drug manufacturing. The company raised €3.92M in 2024 led by Sciety and secured additional investment from Rubicon Healthcare Partners in 2025. With strong revenue growth from SEK 9.8M in 2022 to SEK 33M in 2023, PeptiSystems serves customers across the US, Europe, and Asia including major CDMOs like Corden Pharma.
No open roles listed right now.